GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Business Wire • 06/04/24
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024Business Wire • 05/29/24
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Business Wire • 05/06/24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023Business Wire • 03/27/24
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024Business Wire • 03/13/24
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceBusiness Wire • 02/26/24
GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be RealSeeking Alpha • 01/30/24
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687Business Wire • 01/04/24
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaBusiness Wire • 12/10/23
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceBusiness Wire • 11/09/23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023Business Wire • 11/03/23
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023Business Wire • 10/20/23
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687Business Wire • 09/06/23
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment ConferenceBusiness Wire • 09/05/23